These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 22207876)

  • 1. Bone mass, bone markers and prevalence of fractures in adults with osteogenesis imperfecta.
    Wekre LL; Eriksen EF; Falch JA
    Arch Osteoporos; 2011; 6(1):31-8. PubMed ID: 22207876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mortality and morbidity in patients with osteogenesis imperfecta in Denmark.
    Folkestad L
    Dan Med J; 2018 Apr; 65(4):. PubMed ID: 29619932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists.
    Bradbury LA; Barlow S; Geoghegan F; Hannon RA; Stuckey SL; Wass JA; Russell RG; Brown MA; Duncan EL
    Osteoporos Int; 2012 Jan; 23(1):285-94. PubMed ID: 21739105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Femoral geometric parameters and BMD measurements by DXA in adult patients with different types of osteogenesis imperfecta.
    Kocijan R; Muschitz C; Fratzl-Zelman N; Haschka J; Dimai HP; Trubrich A; Bittighofer C; Resch H
    Skeletal Radiol; 2013 Feb; 42(2):187-94. PubMed ID: 22955449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EFFECTS OF LONG-TERM ALENDRONATE TREATMENT ON A LARGE SAMPLE OF PEDIATRIC PATIENTS WITH OSTEOGENESIS IMPERFECTA.
    Lv F; Liu Y; Xu X; Wang J; Ma D; Jiang Y; Wang O; Xia W; Xing X; Yu W; Li M
    Endocr Pract; 2016 Dec; 22(12):1369-1376. PubMed ID: 27482608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. THE CLINICAL CHARACTERISTICS AND EFFICACY OF BISPHOSPHONATES IN AUDLT PATIENTS WITH OSTEOGENESIS IMPERGECTA.
    Xu XJ; Ma DD; Lv F; Wang JY; Liu Y; Xia WB; Jiang Y; Wang O; Xing XP; Yu W; Li M
    Endocr Pract; 2016 Nov; 22(11):1267-1276. PubMed ID: 27482615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with Pamidronate.
    Lindahl K; Kindmark A; Rubin CJ; Malmgren B; Grigelioniene G; Söderhäll S; Ljunggren Ö; Åström E
    Bone; 2016 Jun; 87():11-8. PubMed ID: 26957348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute and long-term effects of zoledronate in adult patients with osteogenesis imperfecta. An observational Spanish study with five years of follow-up.
    Pavón de Paz I; Rosado Sierra JA; Pérez Blanco C; Modroño Móstoles N; Guijarro de Armas G; Navea Aguilera C
    Endocrinol Diabetes Nutr (Engl Ed); 2019 Feb; 66(2):108-116. PubMed ID: 30077631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosis of Recurrent Fracture in a Pediatric Cohort.
    Fiscaletti M; Coorey CP; Biggin A; Briody J; Little DG; Schindeler A; Munns CF
    Calcif Tissue Int; 2018 Nov; 103(5):529-539. PubMed ID: 29943187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone structure assessed by HR-pQCT, TBS and DXL in adult patients with different types of osteogenesis imperfecta.
    Kocijan R; Muschitz C; Haschka J; Hans D; Nia A; Geroldinger A; Ardelt M; Wakolbinger R; Resch H
    Osteoporos Int; 2015 Oct; 26(10):2431-40. PubMed ID: 25956285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2006; 6(20):1-180. PubMed ID: 23074491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative study of quality of life, functional and bone outcomes in osteogenesis imperfecta with bisphosphonate therapy initiated in childhood or adulthood.
    Feehan AG; Zacharin MR; Lim AS; Simm PJ
    Bone; 2018 Aug; 113():137-143. PubMed ID: 29787832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differing lumbar vertebral mineralization rates in ambulatory pediatric patients with osteogenesis imperfecta.
    Reinus WR; McAlister WH; Schranck F; Chines A; Whyte MP
    Calcif Tissue Int; 1998 Jan; 62(1):17-20. PubMed ID: 9405727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do femoral fractures in adult patients with osteogenesis imperfecta imitate atypical femoral fractures? A case series.
    Andersen JD; Bünger MH; Rahbek O; Hald JD; Harsløf T; Langdahl BL
    Osteoporos Int; 2019 Feb; 30(2):513-517. PubMed ID: 30448959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imaging in osteogenesis imperfecta: Where we are and where we are going.
    Gazzotti S; Sassi R; Aparisi Gómez MP; Moroni A; Brizola E; Miceli M; Bazzocchi A
    Eur J Med Genet; 2024 Apr; 68():104926. PubMed ID: 38369057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alendronate treatment in children with osteogenesis imperfecta.
    Akcay T; Turan S; Guran T; Bereket A
    Indian Pediatr; 2008 Feb; 45(2):105-9. PubMed ID: 18310788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Denosumab for Osteoporosis in Three Female Patients with Osteogenesis Imperfecta.
    Uehara M; Nakamura Y; Takahashi J; Kamimura M; Ikegami S; Suzuki T; Uchiyama S; Yamaguchi T; Kosho T; Kato H
    Tohoku J Exp Med; 2017 Jun; 242(2):115-120. PubMed ID: 28626166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Role of the bone mineral density investigation through measuring of peripheral dual-energetic x-ray absorption in prevention of fractures in children with osteogenesis imperfecta].
    Saganelidze KhZ
    Georgian Med News; 2005 Mar; (120):61-4. PubMed ID: 15855703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial.
    Chevrel G; Schott AM; Fontanges E; Charrin JE; Lina-Granade G; Duboeuf F; Garnero P; Arlot M; Raynal C; Meunier PJ
    J Bone Miner Res; 2006 Feb; 21(2):300-6. PubMed ID: 16418786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Skeletal outcomes of patients with osteogenesis imperfecta during drug holiday of bisphosphonates: a real-world study.
    Zhang Y; Hu J; Lin X; Sun L; Yan S; Zhang Q; Jiang Y; Wang O; Xia W; Xing X; Li M
    Front Endocrinol (Lausanne); 2022; 13():901925. PubMed ID: 36225201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.